Insider Selling: Omnicell, Inc. (OMCL) CFO Sells 1,926 Shares of Stock
Omnicell, Inc. (NASDAQ:OMCL) CFO Peter J. Kuipers sold 1,926 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the sale, the chief financial officer now directly owns 40,544 shares in the company, valued at $2,095,719.36. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down $0.30 during mid-day trading on Monday, hitting $51.45. 223,655 shares of the stock were exchanged, compared to its average volume of 255,569. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Omnicell, Inc. has a 12 month low of $31.85 and a 12 month high of $55.40.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.42. The company had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. Omnicell’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 EPS. equities analysts forecast that Omnicell, Inc. will post 0.12 earnings per share for the current year.
Several equities research analysts have commented on OMCL shares. Cantor Fitzgerald reissued a “buy” rating and set a $60.00 price target on shares of Omnicell in a research report on Wednesday, December 13th. Oppenheimer reissued a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Tuesday, December 5th. Benchmark boosted their price target on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Craig Hallum reaffirmed a “buy” rating and issued a $62.00 target price (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Finally, Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $55.14.
COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/insider-selling-omnicell-inc-omcl-cfo-sells-1926-shares-of-stock/1771690.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.